This newsletter presents you the following key sessions:
1. Video interview with prof. Noel W. Clarke who discusses the overall survival data of patients with metastatic
hormone sensitive prostate cancer treated with hormonal therapy ± docetaxel in the STAMPEDE study
2. Encorafenib-based therapy is life-prolonging in patients with BRAFV600E mutant metastatic colorectal
cancer
3. Dual immunotherapy with nivolumab and ipilimumab represents a potential new first-line treatment option
for patients with advanced non-small cell lung cancer
4. Adding pembrolizumab to platinum-based neoadjuvant chemotherapy leads to an increase in the
pathological response rate in early triple negative breast cancer
5. Cabazitaxel improves radiographic progression-free survival compared to abiraterone or enzalutamide
in metastatic castration-resistant prostate cancer